ArticleFrontiers in immunology2026
Substance P as a potential salivary biomarker to differentiate Sjögren's disease from non-Sjögren sicca syndrome: a pilot study.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: The diagnosis of Sjögren's Disease (SjD) remains challenging due to the non-specific nature of sicca symptoms and the need for invasive biopsies. This pilot study aimed to investigate the potential of salivary Substance P (SP), a neuropeptide involved in glandular regulation and neurogenic inflammation, as a novel, non-invasive biomarker to differentiate patients with SjD from those with non-autoimmune Non-Sjögren sicca syndrome (NSS). Methods: Unstimulated whole saliva samples were collected from three groups of female participants: 13 patients classified as SjD according to ACR/EULAR criteria, 13 patients with idiopathic NSS symptoms who did not meet the criteria, and 13 healthy controls (CTRL). Salivary SP concentrations were measured using a specific enzyme-linked immunosorbent assay (ELISA). Clinical, serological, and histopathological data were recorded for correlation analyses. Receiver operating characteristic (ROC) curve analysis was used to evaluate the diagnostic performance of salivary SP. Results: Salivary SP levels were significantly higher in SjD patients (mean 92.2 ± 15.503 pg/ml) compared to both NSS patients (30.39 ± 4.08 pg/ml, p < 0.005) and healthy controls (39.93 ± 5.97 pg/ml, p < 0.005). No significant difference was found between the NSS and CTRL groups. ROC analysis demonstrated that salivary SP could distinguish SjD from NSS, with an area under the curve (AUC) of 0.8225 (p = 0.005). At a cut-off value of 47.63 pg/ml, sensitivity was 77% and specificity was 85%. A positive association was observed between salivary SP levels and the presence of ANA autoantibodies in the SjD cohort. Conclusion: Salivary SP appears to be elevated in patients with SjD compared to those with NSS in this preliminary study, suggesting a potential diagnostic signal that warrants further investigation. Although the observed differences hint at possible utility as a non-invasive biomarker related to neuroimmune dysregulation, the diagnostic accuracy observed should be interpreted with caution due to the limited sample size and the exploratory nature of the findings. Larger, prospective, and well-powered studies are needed to confirm these preliminary observations, to assess the robustness of salivary SP as a diagnostic tool, and to determine its potential clinical applicability.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.